In Malaysia, the combination of ICI and chemotherapy is registered as a first‐line treatment in advanced NSCLC regardless of PD‐L1 expression, whereas pembrolizumab monotherapy is a first‐line treatment option in patients with PD‐L1 expression >1%. Here, CD274 is linked to non-small cell lung carcinoma.